Conference Report

Conference Report From the 2008 Gastrointestinal Cancers Symposium: Colorectal Cancers

Source: CCO Independent Conference Coverage of the 2008 Gastrointestinal Cancers Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Conference Report From the 2008 Gastrointestinal Cancers Symposium: Colorectal Cancers


Faculty:

Alan P. Venook, MDRichard M. Goldberg, MD
  • Alan P. Venook, MD
  • Richard M. Goldberg, MD

CME CREDIT INFORMATION

Release Date: 03/31/08

Expiration Date: 03/30/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Begin the Conference Report

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss recent clinical trial data regarding the addition of targeted agents to FOLFOX and FOLFIRI regimens for the treatment of metastatic colorectal cancer
  • Explain the association between the efficacy and toxicity profile of capecitabine and 5-fluorouracil/leucovorin in patients with stage III colorectal cancer
  • Describe the role of KRAS as a prognostic factor in the treatment of colorectal cancer
  • Summarize the results of recent studies evaluating patient adherence to follow-up care after treatment for colorectal cancer

Topics covered include:

  • Overview
  • The PACCE Study: Chemotherapy Plus Bevacizumab With or Without Panitumumab in Metastatic Colorectal Cancer
  • New CONcePT in Oxaliplatin Neurotoxicity Prevention: Calcium and Magnesium Added to FOLFOX/Bevacizumab
  • Capecitabine vs 5-FU/Leucovorin: The X-ACT Trial, Long-term Follow-up
  • 5-FU/Irinotecan in Elderly Patients With mCRC
  • Follow-up Care After Curative Resection for CRC
  • KRAS Status as a Predictor of Response to EGFR-Targeted Therapy
  • Reading Tumors’ Genetic Signatures for Clues to Prognosis
  • Circulating Tumor Cells as a Prognostic Marker
  • Insurance Status and Stage at Diagnosis
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.